Eliciting patients’ preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment
- 9 June 2012
- journal article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 21 (1), 245-251
- https://doi.org/10.1007/s00520-012-1517-5
Abstract
Studies have demonstrated that patients at low risk for febrile neutropenia (FN) complications can be treated safely and effectively at home. Information on patient preferences for outpatient treatment of this condition will help to optimize health care delivery to these patients. The purpose of this study was to elicit non-Hodgkin lymphoma patients’ preferences on attributes related to outpatient treatment of FN. We used a self-administered discrete choice experiment questionnaire based on the attributes of out-of-pocket costs, unpaid caregiver time required daily, and probability of return to the hospital. Ten paired scenarios in which levels of the attributes were varied were presented to study patients. For each pair, patients indicated the scenario they preferred. Adjusted odds ratios (ORs) of accepting a scenario that described outpatient care for FN were estimated. Eighty-eight patients completed the questionnaire. Adjusted ORs [95 % confidence intervals] of accepting outpatient care for FN were 0.84 [0.75, 0.95] for each $10 increase in out-of-pocket cost; 0.82 [0.68, 0.99] for each 1 h increase in daily unpaid caregiver time; and 0.53 [0.50, 0.57] for each 5 % increase in probability of return to the hospital. Probability of return to the hospital was the most important attribute to patients when considering home-based care for FN. Patients considered out-of-pocket costs and unpaid caregiver time to be less important than probability of return to the hospital. This study identifies factors that could be incorporated into outpatient delivery systems for FN care to ensure adequate patient uptake and satisfaction with such programs.Keywords
This publication has 22 references indexed in Scilit:
- Costs of Home Versus Inpatient Treatment for Fever and Neutropenia: Analysis of a Multicenter Randomized TrialJournal of Clinical Oncology, 2011
- Evaluation of direct medical costs of hospitalization for febrile neutropeniaCancer, 2009
- Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practiceSupportive Care in Cancer, 2007
- Patient preferences for managing asthma: results from a discrete choice experimentHealth Economics, 2007
- Outpatient Oral Antibiotics for Febrile Neutropenic Cancer Patients Using a Score Predictive for ComplicationsJournal of Clinical Oncology, 2006
- The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephoneSupportive Care in Cancer, 2006
- Quick and easy choice sets: Constructing optimal and nearly optimal stated choice experimentsInternational Journal of Research in Marketing, 2005
- Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapyEuropean Journal of Cancer, 1995
- The Costs of Treating Febrile Neutropenia in Patients with Malignant Blood DisordersPharmacoEconomics, 1994
- Economic study of neutropenia induced by myelotoxic chemotherapyPharmacy World & Science, 1994